Jaypirca Approved for Relapsed/Refractory Mantle Cell Lymphoma
As a noncovalent inhibitor of BTK, pirtobrutinib is able to reestablish BTK inhibition in patients previously treated with covalent BTK inhibitors.
Diagnosis & Disease Information
ASH 2022: MCL Trials Break New Ground, May Change Practice
Mantle cell lymphoma trials presented at ASH 2022 have broken new ground, shown promising results, and may change practice, according to researchers.
Adding Ibrutinib to Induction and Maintenance Improves FFS in Mantle Cell Lymphoma
Adding ibrutinib to induction and maintenance after transplant improves failure-free survival in patients with mantle cell lymphoma, results of the TRIANGLE study suggest.
Zandelisib Plus Zanubrutinib Elicits High ORRs in Relapsed/Refractory FL or MCL
The combination of zandelisib and zanubrutinib produced high overall response rates in patients with relapsed/refractory follicular lymphoma or mantle cell lymphoma.
BTK Inhibitor With CAR T-Cell Therapy Deemed Effective in Relapsed/Refractory MCL
The combination of ibrutinib and tisagenlecleucel produced durable responses in patients with relapsed/refractory mantle cell lymphoma.
Outcomes After BTK Inhibitor Failure in Rel/Ref Mantle Cell Lymphoma
A real-world study provides a benchmark for survival in MCL patients for whom BTK inhibitor treatment has failed, according to researchers.
Bendamustine-Rituximab Induction Appears Effective in Mantle Cell Lymphoma
First-line bendamustine plus rituximab followed by ASCT and rituximab maintenance appears effective in mantle cell lymphoma.
Real-World Analysis Reveals Treatment, Survival Trends in Mantle Cell Lymphoma
Researchers sought to determine the treatment and survival trends for patients with mantle cell lymphoma.
New Tablet Formulation of Calquence Approved for CLL, SLL, MCL
The approval was based on data from the phase 1 ELEVATE-PLUS trials, which showed that acalabrutinib 100 mg tablets were bioequivalent to the acalabrutinib 100 mg capsules.
Real-World Treatment Outcomes, Roles of Transplant and Maintenance Rituximab in Mantle Cell Lymphoma
ASCT as first-line treatment for patients with MCL appears to be underutilized in the US community setting.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...